The year in charts

The year in charts

Tuesday, April 25, 2023 @ 7:00 am

Capital investments in Swiss biotech companies 2012-2022

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Total Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022 — Note: The 2022 data in above tables is based on information that was available up until March 31, 2023. At this time, some of the companies had not yet disclosed
their financial figures for 2022. Therefore some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e. Q3 or Q4 2022).

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Public Swiss Biotech Companies

Revenues, R&D expenses, profit/loss, liquidity 2020-2022

Private Swiss Biotech Companies

Number of biotech companies in Switzerland 2013-2022

Number of employees in Swiss R&D biotech companies 2020-2022

Tags

You may also be interested in

Active fraud campaign — updated warning for Swiss Biotech Day 2026

We are tracking an ongoing and escalating fraud campaign targeting Swiss Biotech Association members and Swiss Biotech Day participants. Multiple fraudulent domains and Gmail accounts have already been identified and reported to their registrars and hosts; several have been taken down, but new ones continue to appear. Please read this alert carefully and share it within your organization.
April 16, 2026

Quant Biomarkers secures Innosuisse funding for kidney disease diagnostics

Quant Biomarkers AG has secured around CHF 1 million in non-dilutive grant funding from Innosuisse to support the development and clinical validation of a biomarker test for earlier detection, progression assessment, and treatment monitoring of chronic kidney disease. The Innovation project supported by Innosuisse is advancing cutting-edge translational diagnostics through a strategic collaboratio
January 22, 2026

ALP Bio AG raises CHF 1.75 million pre-seed to de-risk antibody development

ALP Bio AG, a Schlieren-based biotech, has closed a CHF 1.75M pre-seed round led by Munich-based 42CAP, with participation from Venture Kick and angel investors. The funding will accelerate ALP Bio's platform, which combines human immune organoid biology with generative AI to help antibody developers identify and reduce immunogenicity risk earlier in drug development.
April 30, 2026

arcoris bio and Betta Scientific: Collaboration to accelerate global market expansion

arcoris bio, an innovative biotech company, and Betta Scientific have entered a strategic collaboration to accelerate global market access of arcoris bio’s multiplex immunofluorescence kits. Leveraging Betta Scientific’s expertise in business-to-consumer strategy and distribution network development, the partnership will expand presence across Europe, APAC, and the Americas.
April 27, 2026

Pharvaris: Evidence for the potential of combined therapy for bradykinin-mediated angioedema

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), presented data evaluating safety margins of administration of deucrictibant immediate-release
April 20, 2026

Cosmo flash update: Positive 12-month phase III topline results

April 15, 2026